WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE

Saved in:
Bibliographic Details
Main Authors: Vlado Perkovic, Katherine Tuttle, Naveed Sattar, A. Michael Lincoff, Ann M. Navar, Nikolaus Marx, Anders Hvelplund, Florian M.M. Baeres, Mads D. Engelmann, G. Kees Hovingh, Paul M. Ridker
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492403376X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849330183019954176
author Vlado Perkovic
Katherine Tuttle
Naveed Sattar
A. Michael Lincoff
Ann M. Navar
Nikolaus Marx
Anders Hvelplund
Florian M.M. Baeres
Mads D. Engelmann
G. Kees Hovingh
Paul M. Ridker
author_facet Vlado Perkovic
Katherine Tuttle
Naveed Sattar
A. Michael Lincoff
Ann M. Navar
Nikolaus Marx
Anders Hvelplund
Florian M.M. Baeres
Mads D. Engelmann
G. Kees Hovingh
Paul M. Ridker
author_sort Vlado Perkovic
collection DOAJ
format Article
id doaj-art-69191d769cde4e58be52c194904b1203
institution Kabale University
issn 2468-0249
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-69191d769cde4e58be52c194904b12032025-08-20T03:47:02ZengElsevierKidney International Reports2468-02492025-02-01102S767S76810.1016/j.ekir.2024.11.1354WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASEVlado Perkovic0Katherine Tuttle1Naveed Sattar2A. Michael Lincoff3Ann M. Navar4Nikolaus Marx5Anders Hvelplund6Florian M.M. Baeres7Mads D. Engelmann8G. Kees Hovingh9Paul M. Ridker10The George Institute for Global Health, The University of New South Wales, Sydney, AustraliaSchool of Medicine, University of Washington and Providence Inland Northwest Health, Spokane, United StatesSchool of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, United KingdomDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, United StatesDepartment of Internal Medicine, University of Texas Southwestern Medical Centre, Dallas, United StatesDepartment of Internal Medicine I, University Hospital Aachen, Aachen, GermanyGlobal Development Projects, Novo Nordisk A/S, Søborg, DenmarkGlobal Medical Affairs, Novo Nordisk A/S, Søborg, DenmarkClinical Drug Development, Novo Nordisk A/S, Søborg, DenmarkGlobal Chief Medical Office, Novo Nordisk A/S, Søborg, DenmarkCenter for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, United Stateshttp://www.sciencedirect.com/science/article/pii/S246802492403376X
spellingShingle Vlado Perkovic
Katherine Tuttle
Naveed Sattar
A. Michael Lincoff
Ann M. Navar
Nikolaus Marx
Anders Hvelplund
Florian M.M. Baeres
Mads D. Engelmann
G. Kees Hovingh
Paul M. Ridker
WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
Kidney International Reports
title WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
title_full WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
title_fullStr WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
title_full_unstemmed WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
title_short WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE
title_sort wcn25 888 design of the zeus trial interleukin 6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease
url http://www.sciencedirect.com/science/article/pii/S246802492403376X
work_keys_str_mv AT vladoperkovic wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT katherinetuttle wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT naveedsattar wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT amichaellincoff wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT annmnavar wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT nikolausmarx wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT andershvelplund wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT florianmmbaeres wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT madsdengelmann wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT gkeeshovingh wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease
AT paulmridker wcn25888designofthezeustrialinterleukin6inhibitionwithziltivekimabforcardiovascularprotectioninchronickidneydisease